Meeting
2023 ASCO Annual Meeting
CfDNA NGS detection of fusions acquired as mechanisms of resistance in the post-EGFR setting across multiple solid tumors.
Authors
Arielle Yablonovitch
Guardant Health, Palo Alto, CA
Arielle Yablonovitch , Nicole Zhang , Leylah Drusbosky , Reagan Barnett , Jennifer Yen , Shile Zhang , Han-Yu Chuang , Scott Kopetz , Jonathan M. Loree , Van K. Morris II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3053)
DOI
10.1200/JCO.2023.41.16_suppl.3053
Abstract #
3053
Poster Bd #
251
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.
First Author: Dazhi Liu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Novel potential mechanisms of acquired resistance to anti-EGFR monoclonal antibody (mAb) therapy detected in liquid biopsies (LBx) from patients (pts) with advanced colorectal cancer (CRC).
First Author: Christine Megerdichian Parseghian
First Author: Mohamed E. Salem
Poster
2023 ASCO Quality Care Symposium
Real-world treatment patterns and clinical outcomes post standard of care (SOC) among patients (pts) with metastatic non-small cell lung cancer (mNSCLC) with and without actionable genomic alterations (AGAs) in the United States (US).
First Author: Ruchit Shah